William Shergy, MD
Associate Clinical Professor of Medicine
University of Alabama at Birmingham
School of Medicine
Huntsville, Alabama
Assistant Consulting Professor of Medicine
Duke University Medical Center
Durham, North Carolina
Related Videos
Video
What percentage of patients started on a TNFI will respond and to what degree will they respond?
What percentage of patients started on a TNFI will respond and to what degree will they respond?
Video
What specific pattern of treatment response failures do you require to switch a patient from a TNFI to an IL-6 inhibitor of co-stimulatory blockade?
Video
Can you summarize the key features of the new guidelines for RA issued by the ACR?
Can you summarize the key features of the new guidelines for RA issued by the ACR?
Video
What is the role of B-cell depletion therapy in RA?
What is the role of B-cell depletion therapy in RA?
Video
Trials evaluating IL-6 inhibitors such as sarilumab in RA patients have used global function and disability as outcome benchmarks for assessing patient outcomes? What are the findings and why is this important?
Video
How important are quality-of-life measures in RA and how effective are IL-6 inhibitors in this regard compared to TNFIs according to the latest clinical studies?
Video
Do the trials with the IL-6 inhibitor sarilumab suggest any differences between this agent and the establish IL-6 inhibitor indicated for RA?